Targeting prostatic tumor micro-environment to address therapy resistance

Cure or control of disseminated disease remains the greatest challenge facing cancer clinicians and scientists, and is the greatest cause of patient mortality. Predominantly, the cancer related deaths stem from the growth and development of disease that is resistant to the killing effects of available oncolytic therapies. Much attention has been given to the overexpression of cellular drug transporters (e.g., MDR1) and changes associated in drug kinetics (1-6), however, over the past decade numerous reports have linked tumor heterogeneity as the root cause in the development of therapy resistant.